Overview

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Phase I/II Study in Patients With Small Cell Lung Cancer (SCLC) of Veliparib in Combination With Topotecan
Phase:
Phase 1
Details
Lead Sponsor:
Central European Society for Anticancer Drug Research
Treatments:
Poly(ADP-ribose) Polymerase Inhibitors
Topotecan
Veliparib